In the interest of balancing the gender gap here, another pharmaceutical company has come up with a spanking new drug with a very masculine name, Provenge, to treat "untreatable" prostate cancer. This baby offers probably more "hope" than Avastin, and does it for men. And amazingly, it's more expensive. Provenge costs $93,000 for a treatment. And Medicare takes care of it. One great thing about Provenge is that a higher percentage of men will acquire prostate cancer than women will suffer breast cancer. Ka-ching! And they don't have those wussy income statements, they're not discounting the drug.
|screenshot of customized Google News this AM, 7/1/2011|
Again we have a handy transfusion at the end of life of a nice big chunk of the stricken patient's assets. And when the government pays for it, why it's transfusing the citizen's pre-entitled future benefits right into the corporate coffers of big pharma as well.
I, for one, am relieved this gross gender disparity has been settled, finally. Hope is equally expensive for men and women. Mutter, mutter, mutter.